SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that neocloud providers face failures and consolidation has intensified selling in CoreWeave and renewed concern about its debt-heavy, capital-intensive AI infrastructure model and access to financing. Traders debate whether Musk is criticizing a competitor for self-interest, while bulls point to AI demand and Nvidias backing and bears focus on borrowing costs, dilution, and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure alongside AI data-center and neocloud stocks as traders debate financing risks and Elon Musks warning that tighter credit could trigger failures among smaller operators. Bears fear debt, dilution and execution challenges, while bulls argue IRENs contracts, power access and AI partnerships distinguish it and point to continued compute demand.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp neocloud selloff tied to Elon Musks warning of tighter financing and consolidation among AI infrastructure providers, intensifying concerns about debt-funded expansion and data-center returns. Traders disagree on whether Nebius is vulnerable to sector-wide risks or better positioned because of its financing access and demand for AI compute.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Merck are driving discussion: traders broadly view the data as clinically promising, but the shares sold off as investors judged them against high expectations after a sharp rally. Bulls see validation for a broader cancer-vaccine platform, while bears question its commercial potential, costs and valuation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs REGAL Phase 3 trial of GPS for AML, with traders watching for the 80th survival event that would trigger final analysis and eventual topline results. The prolonged wait and company silence fuel debate: bulls speculate that slower event accrual reflects longer survival and possible ASH-related disclosure, while skeptics warn that the delay is uncertain and could signal problems; SLS009 data is a secondary focus.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazilian equities sold off sharply after Lulas election victory, as traders voiced concerns about policy and economic uncertainty; some alleged election irregularities without evidence. Others called the move an overreaction and viewed the drop as a buying opportunity.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals steep selloff is dominating discussion, with traders citing the recent convertible offering and dilution concerns, possible hedging-related selling, and broader weakness in AI data-center stocks. Some see its contracted data-center business and expansion pipeline as long-term support, while others worry about financing, execution, and the upcoming earnings report.

Lufax Holding Ltd. operates a technology-empowered personal financial services platform. It offers personal lending and wealth management solutions. The company was founded in August 2005 and is headquartered in Shanghai, China.

Lufax Holding Ltd - ADR

Lufaxs preliminary Q3 loss warning and planned reverse split are driving debate ahead of the full results: bearish traders see more evidence of business and shareholder risk, while some holders argue tax charges and credit provisions may distort the headline loss and are watching loan quality and originations for signs of improvement. Discussion also reflects broader weakness across Chinese fintech lenders and mistrust of management.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and steep underperformance versus Bitcoin dominate discussion, with traders focused on the lack of signed AI/data-center tenants and uncertainty around the Long Ridge deal and financing. Bears cite debt, dilution and management concerns, while bulls see an oversold setup and argue Bitcoin strength or a lease announcement could support a rebound.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL neoadjuvant colon-cancer data, including a reported 72% pathologic complete response rate in a small Phase 2 dMMR cohort, are driving attention; traders highlight the possibility of organ preservation. Optimists see promising efficacy, while skeptics question the early, limited dataset and stress the need for durable results and confirmatory Phase 3 progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 31.65% on an annualized basis producing an average annual return of 42.52%. Currently, Krystal Biotech has a market capitalization ofread more...

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.read more...

Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.16% on an annualized basis producing an average annual return of 44.36%. Currently, Krystal Biotech has a market capitalization ofread more...

Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.48% on an annualized basis producing an average annual return of 43.76%. Currently, Krystal Biotech has a market capitalization ofread more...

Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?

KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.

Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Krystal Biotech (NASDAQ:KRYS) has outperformed the market over the past 5 years by 32.97% on an annualized basis producing an average annual return of 44.08%. Currently, Krystal Biotech has a market capitalization ofread more...

Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Krystal Biotech Inc

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Jefferies noted that the company delivered another strong quarter, with Vyjuvek topline U.S. revenue growth re-accelerating with robust demand, reaching about 60% penetration.&nbsp;</li><li>Krystal reported Q4 diluted earnings per share of $1.70, up from the $1.52 reported in the corresponding quarter of 2024, and above an analyst estimate of $1.47.&nbsp;</li><li>Krystal’s Vyjuvek is a gene therapy approved for the treatment of Dystrophic Epidermolysis Bullosa.</li></ul> Shares of Krystal Biotech (KRYS) rose 5% on Tuesday after Jefferies hiked its price target on the stock on the heels of the company’s fourth-quarter (Q4) earnings that beat Wall Street expectations.&nbsp; Jefferies analyst Roger Song raised the firm's price target on Krystal Biotech to $371 from $310 and kept a ‘Buy’ rating on the shares after meeting with company management, as per TheFly. The new price target represents a potential upside of about 34% from the stock’s closing price on Friday.The firm noted that the company delivered another strong quarter, with Vyjuvek topline U.S. revenue growth re-accelerating with robust demand, reaching about 60% penetration and ex-U.S. expansion likely to become a 2026 growth driver. Pipeline continues to mature, with two ophthalmology programs in pivotal trials with data in 2026, and two more nearing pivotal, Jefferies added.<h2 class="st-heading-2">Krystal’s Q4 Earnings</h2>Krystal reported Q4 diluted earnings per share of $1.70, up from the $1.52 reported in the corresponding quarter of 2024, and above an analyst estimate of $1.47, according to data from Fiscal AI.The company recorded $107.1 million in Vyjuvek net product revenue for the fourth quarter, up from $91.1 million in the corresponding quarter of 2024. Vyjuvek is a gene therapy approved for the treatment of Dystrophic Epidermolysis Bullosa, a rare, inherited genetic disorder characterized by severe skin fragility, where minimal friction causes blisters, erosions, and scarring. &nbsp;The company said that it has secured over 660 reimbursement approvals for Vyjuvek in the United States and high patient demand is driving steady Vyjuvek uptake since launch in Germany, France, and Japan.For 2026, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-fourth-quarter-and-full-year-2025">expects </a>adjusted research and development as well as selling, general and administrative expenses to add up to $175 million-$195 million, lower than the $204.7 million reported for 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KRYS stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/KRYS">KRYS stock</a> has gained 85% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-robotaxis-reportedly-involved-in-14-crash-incidents-since-launch/cZRWMUpR4HG">Tesla Robotaxis Reportedly Involved In 14 Crash Incidents Since Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Krystal Biotech logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Jefferies’ new price target represents a potential upside of about 34% from the stock’s closing price on Friday. 

iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$311.50
Prev Close	$320.13
Open	$318.91
Dividend Yield	0.00%
50-Day Moving Average	$338.84
Beta	0.98
Avg. Volume	279,994.22
PE Ratio	39.04

52-Week High	$382.54
52-Week Low	$183.26
Market Capitalization	$9.22B
EPS (Annual)	$6.84
Price to Book	6.78
Revenue Per Employee	$1.32M

Feed

News

Sentiment

Earnings

Fundamentals

Info

KRYS Fundamentals